A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507154-32-00

Acronym

M15-531

Enrollment

Registered

2023-11-27

Start date

2017-02-17

Completion date

2025-12-02

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndromes (MDS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026